Indeed, the blocking anti-GARP:TGF-β1 mAb exerted anti-tumor efficacy in platelets-specific Lrrc32 KO mice, but lost its activity in Tregs-specific Lrrc32 KO mice. The gene discussed is LRRC32; the disease is neoplasm.